Recombinant IL2RA (Daclizumab Biosimilar) anticorps

N° du produit ABIN7487796

Cet anticorps anti-IL2RA (Daclizumab Biosimilar) est un anticorps Monoclonal produit chez le Mammalian Cells, détectant IL2RA (Daclizumab Biosimilar) dans ELISA. Convient pour Humain.

Aperçu rapide pour Recombinant IL2RA (Daclizumab Biosimilar) anticorps (ABIN7487796)

Antigène: IL2RA (Daclizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp IL2RA (Daclizumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-IL2RA (Daclizumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Daclizumab Biosimilar - Anti-IL2RA mAb

Attributs du produit: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur IL2RA (Daclizumab Biosimilar)

Antigène: IL2RA (Daclizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: BIIB019,DAC HYP
Daclizumab is a humanized IgG1 monoclonal antibody that binds to human interleukin 2 receptor (anti-Tac or anti-CD25)and composed of human >90%) and murine (10%) antibody sequences. The human sequence is derived from the constant domain of human IgG1 and the variable framework region of Eu myeloma antibody. The murine part was taken from the complementarity-determining regions of a murine anti-Tac antibody. Daclizumab has been used for preventing acute organ rejection in de novo allogeneic kidney transplantation when used simultaneously with immunosuppressive regimens such as cyclosporine and corticosteroid and in the treatment of adult patients with relapsing multiple sclerosis. These trademarks were Zenapax and Zimbryta, respectively.

Numéro CAS: 152923-56-3